Press Releases

18th January 2021: Metrion Biosciences and LifeArc further extend neuroscience-focused ion channel drug discovery collaboration.

3^rd December 2019: Metrion Biosciences and LifeArc extend ion channel drug discovery collaboration to accelerate neuroscience-focused research

8^th April 2019: Metrion Biosciences appoints Dr Andrew Southan as Chief Executive Officer

1^st April 2019: Metrion Biosciences closes funding round

29^th January 2019: Metrion Biosciences and LifeArc sign collaboration agreement for neuroscience-focused ion channel drug discovery.

17^th September 2018: Metrion Biosciences makes senior appointments to strengthen its drug discovery leadership team 

05^th September 2018: Metrion Biosciences and AMRI collaborate to offer ion channel drug discovery services.

28^th August 2018: Metrion awarded £637k Innovate UK Biomedical Catalyst primer award.

05^th March 2018: Metrion appoints two new Board Directors.

12^th February 2018: Metrion Biosciences establishes Scientific Advisory Board.

5^th February 2018: Metrion Biosciences awarded £200k funding under Innovate UK Biomedical Catalyst FeasibilityAward.

29^th January 2018: Metrion Biosciences acquires rights to small molecule potassium channel inhibitors from Japan Tobacco Inc.

16^th January 2018: Metrion Biosciences opens £600k investment round through SyndicateRoom to support growth of service business.

31^st July 2017: LifeArc and Metrion Biosciences extend partnership to support LifeArc’s neuroscience small molecule drug discovery programme.

2^nd May 2017: Metrion Biosciences appoints Chief Operating Officer and Head of Business Development.

24^th April 2017: Metrion Biosciences and Venomtech announce collaboration to search for novel modulators of ion channels with proven therapeutic potential.

15^th March 2017: Metrion Biosciences and Concept Life Sciences Introduce Integrated Ion Channel Drug Discovery Service.

7^th November 2016: Axiogenesis and Metrion announce stem cell collaboration.

17^th October 2016: Metrion Expands Operations.

23^rd August 2016: Metrion Biosciences Joins CRACK IT “DRGNET” Human Pain Research Consortium.

26^th July 2016: Axol Bioscience and Metrion Biosciences Announce Research Collaboration to Study Human Stem Cell-Derived Cardiomyocytes for Cardiac Safety and Drug Discovery Applications.

21^st March 2016: Metrion Biosciences receives funding to work on human stem cell-derived iPS cardiomyocytes to create better cardiac safety assays.

22^nd October 2015: Metrion Biosciences becomes and independent CRO.

13^th May 2015: Xention introduces Metrion Biosciences, a Specialist Ion Channel Screening Business.